Zanamivir

被引:23
作者
Waghorn, SL [1 ]
Goa, KL [1 ]
机构
[1] Adis Int Ltd, Auckland 10, New Zealand
关键词
D O I
10.2165/00003495-199855050-00015
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Zanamivir is the first of a new class of selective influenza virus neuraminidase inhibitors. It inhibits both influenza A and influenza B virus replication in vitro. In the ferret model of influenza, zanamivir reduced viral replication and diminished pyrexia associated with the infection. Repeated passage of influenza virus in the presence of zanamivir could produce resistance in vitro. However, there have been no changes in sensitivity to zanamivir in any influenza virus isolates from patients receiving zanamivir in clinical trials. In experimental infection in humans, in which the virus replicates only in the nasal passages, intranasal zanamivir (3.6 to 16mg) prevented infection with influenza virus. A combination of inhaled (10mg) and intranasal (6.4mg) zanamivir for 14 days was effective in preventing influenza in a nursing home setting during an influenza A virus outbreak. Inhaled zanamivir (10mg) with or without intranasal zanamivir (6.4mg) reduced the time to alleviation of influenza symptoms compared with placebo in patients with confirmed infection.
引用
收藏
页码:721 / 725
页数:5
相关论文
共 21 条
[1]  
AOKI F, 1997, 37 INT C ANT AG CHEM, P384
[2]  
BARNETT J, 1997, 37 INT C ANT AG CHEM, P280
[3]  
Bethell R C, 1997, Expert Opin Investig Drugs, V6, P1501, DOI 10.1517/13543784.6.10.1501
[4]  
Colacino Joseph M., 1997, Journal of Infectious Diseases, V176, pS66, DOI 10.1086/514179
[5]  
EFTHYMIOPOULOS C, 1994, 34 INT C ANT AG CHEM, P265
[6]   AMANTADINE AND RIMANTADINE PROPHYLAXIS OF INFLUENZA-A IN NURSING-HOMES - A TOLERABILITY PERSPECTIVE [J].
GUAY, DRP .
DRUGS & AGING, 1994, 5 (01) :8-19
[7]   Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en [J].
Gubareva, LV ;
Robinson, MJ ;
Bethell, RC ;
Webster, RG .
JOURNAL OF VIROLOGY, 1997, 71 (05) :3385-3390
[8]   Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza [J].
Hayden, FG ;
Treanor, JJ ;
Betts, RF ;
Lobo, M ;
Esinhart, JD ;
Hussey, EK .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (04) :295-299
[9]   Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections [J].
Hayden, FG ;
Osterhaus, ADME ;
Treanor, JJ ;
Fleming, DM ;
Aoki, FY ;
Nicholson, KG ;
Bohnen, AM ;
Hirst, HM ;
Keene, O ;
Wightman, K .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (13) :874-880
[10]   ANTIINFLUENZA VIRUS ACTIVITY OF THE NEURAMINIDASE INHIBITOR 4-GUANIDINO-NEUSAC2EN IN CELL-CULTURE AND IN HUMAN RESPIRATORY EPITHELIUM [J].
HAYDEN, FG ;
ROLLINS, BS ;
MADREN, LK .
ANTIVIRAL RESEARCH, 1994, 25 (02) :123-131